This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cancer Vaccines: From First-in-Class To Best-in-Class?

Our Analysis includes:

* Head-to-head target competing analysis* Significant drug target overlap analysis* Cross-sectional R&D profiling of individual drug targets.* Cross-over analysis of target strategies among different tumor types.* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company's pipeline: - Where are we?- Where is our general and specific competition?- What is the level of competition where we want to be?* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company's interest in the cancer vaccine pipeline by:

* Better identifying benchmarking peers* Providing rationale for in/out licensing decisions of drug candidates* Performing proper drug due diligence* Strategies for commercial planning* Guiding Research & Development efforts

Table of Contents

1 Executive Summary 32 About Cancer Highlights - A Module of the DevOnc Platform 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 63 Methodology 73.1 Cancer Highlights' Five Pillar Drug Assessment 74 Table of Contents 94.1 List of Figures 194.2 List of Tables 195 Introduction 285.1 The Scope of this Report 285.2 Definitions 315.3 Abbreviations 316 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment 326.1 Drug Repositioning in Oncology 326.2 Introduction to Targets of Cancer Vaccine Drugs 336.2.1 Acid Phosphatase Activity Targets 386.2.2 Carboxypeptidase Activity Targets 396.2.3 Catalytic Activity Targets 416.2.4 Cell Adhesion Molecule Activity Targets 436.2.5 Chaperone Activity Targets 526.2.6 Cofactor Binding Targets 546.2.7 Complement Activity Targets 566.2.8 Cytokine Activity Targets 586.2.9 DNA Binding Targets 68 6.2.10 DNA Topoisomerase Activity Targets 70 6.2.11 DNA-directed DNA Polymerase Activity Targets 71 6.2.12 Growth Factor Activity Targets 72 6.2.13 GTPase Activity Targets 79 6.2.14 Heat Shock Protein Activity Targets 81 6.2.15 Hormone Activity Targets 83 6.2.16 Isomerase Activity Targets 84 6.2.17 Kinase Binding Targets 85 6.2.18 Kinase Regulator Activity Targets 86 6.2.19 Metallopeptidase Activity Targets 88 6.2.20 MHC Class I Receptor Activity Targets 90 6.2.21 Molecular Function Unknown Targets 93 6.2.22 Oxidoreductase Activity Targets 112 6.2.23 Peptidase Activity Targets 114 6.2.24 Peptide Hormone Targets 123 6.2.25 Protein Binding Targets 126 6.2.26 Protein Serine/Threonine Kinase Activity Targets 128 6.2.27 Protein-tyrosine Kinase Activity Targets 130 6.2.28 Receptor Activity Targets 133 6.2.29 Receptor Binding Targets 147 6.2.30 Receptor Signaling Complex Scaffold Activity Targets 152 6.2.31 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 154 6.2.32 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets 155 6.2.33 RNA-directed DNA Polymerase Activity Targets 156 6.2.34 Serine-type Peptidase Activity Targets 158 6.2.35 T Cell Receptor Activity Targets 161 6.2.36 Transcription Factor Activity Targets 164 6.2.37 Transcription Regulator Activity Targets 169 6.2.38 Translation Regulator Activity Targets 170 6.2.39 Transmembrane Receptor Activity Targets 171 6.2.40 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 173 6.2.41 Transporter Activity Targets 186 6.2.42 Other Targets 1916.3 Mutation Profiles of Cancer Vaccine Drug Targets 2016.3.1 Targets of Cancer Vaccine Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 2016.4 Target-Target Interactions among Identified Targets of Cancer Vaccine Drugs 2056.5 Protein Expression Levels of Identified Targets of Cancer Vaccine Drugs 2086.6 The Drug-Target Competitive Landscape 2106.7 Pathway Assessment of Cancer Vaccine Drugs 2146.7.1 Tools for Analysis of Cancer Pathways 2156.7.2 Pathway Assessment 2167 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs 2467.1 First-in-Class and Me-too in Marketed Drugs 2497.2 First-in-Class and Me-too in Phase III Clinical Development 2507.3 First-in-Class and Me-too in Phase II Clinical Development 2527.4 First-in-Class and Me-too in Phase I Clinical Development 2557.5 First-in-Class and Me-too in Preclinical Development 2587.6 Drug Target Strategies of Suspended or Terminated Cancer Vaccine Drugs 2618 Is First-in-Class the Best-in-Class? 2638.1.1 Marketed 2668.1.2 Phase III 2698.1.3 Phase II 2938.1.4 Phase I 3258.1.5 Preclinical 3398.1.6 Suspended 3588.1.7 Ceased 3599 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy 3879.1 Small Molecules 3899.1.1 Background 3899.1.2 Target Strategies of Small Molecule Drugs 3909.2 Peptide & Protein Drugs 3929.2.1 Background 3929.2.2 Target Strategies of Peptide and Protein Drugs 3939.3 Antibodies 4009.3.1 Background 4009.3.2 Target Strategies of Antibody Drugs 4009.4 Nucleic Acid Therapies 4039.4.1 Background 4039.4.2 Target Strategies of Nucleic Acid Drugs 4049.5 Cell & Gene Therapy 4079.5.1 Background 4079.5.2 Target Strategies of Cell and Gene Therapy Drugs 40810 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 41411 Selecting Indications for Cancer Vaccine Drugs 41711.1 Acute Lymphocytic Leukemia 42011.2 Acute Myelogenous Leukemia 42111.3 Acute Promyelocytic Leukemia 42311.4 Anal Dysplasia 42411.5 B-cell Lymphoma 42511.6 Biliary Cancer 42611.7 Bladder Cancer 42711.8 Bone Cancer 42811.9 Brain Cancer 42911.10 Breast Cancer 43111.11 Cancer (general) 43411.12 Cervical Cancer 43511.13 Cervical Dysplasia 43811.14 Chronic Myelogenous Leukemia 44011.15 Colorectal Adenoma 44111.16 Colorectal Cancer 44211.17 Endometrial Cancer 44511.18 Fallopian Tube Cancer 44611.19 Gastrointestinal Cancer (general) 44711.20 Gastrointestinal Stomach Cancer 44811.21 Glioma 44911.22 Head and Neck Cancer 45011.23 Hematological Cancer (general) 45211.24 Leukemia (general) 45311.25 Liver Cancer 45411.26 Lung Cancer (general) 45511.27 Lymphoma (general) 45811.28 Melanoma 45911.29 Merkel cell carcinoma 46211.30 Mesothelioma 46311.31 Myelodysplastic Syndrome 46411.32 Myeloma 46511.33 non-Hodgkin's Lymphoma 46611.34 Non-Small Cell Lung Cancer 46711.35 Oesophageal Cancer 46911.36 Osteo Sarcoma 47011.37 Ovarian Cancer 47111.38 Pancreatic Cancer 47311.39 Peritoneal Cancer 47511.40 Prostate Cancer 47611.41 Radio/chemotherapy-induced Bone Marrow Injury (general) 47911.42 Renal Cancer 48011.43 Sarcoma (general) 48211.44 Skin Cancer (general) 48311.45 Small Cell Lung Cancer 48411.46 Soft Tissue Sarcoma 48511.47 Solid Tumor 48611.48 Squamous Cell Carcinoma 48711.49 T-cell Lymphoma 48811.50 Thyroid Cancer 48911.51 Unspecified Cancer Indication 49011.52 Vaccine adjunct 49212 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company 49312.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 49612.2 Company Facts and Ranking 49812.3 Competitive Fall-Out Assessment 50512.4 AC Immune 50712.5 Adaptimmune 51012.6 Advaxis 51512.7 Agenus 52312.8 Aida Pharmaceuticals 52812.9 AlphaVax 53112.10 Amgen 53812.11 Anza Therapeutics 54112.12 Argos Therapeutics 54512.13 Astellas 54812.14 AstraZeneca 55112.15 Bavarian Nordic 55412.16 Bellicum Pharmaceuticals 56012.17 Biogen Idec 56312.18 BioNTech 56712.19 BioSante 57012.20 Biostar 57512.21 BioVex 57812.22 BreakThrough Therapeutics 58112.23 Bristol-Myers Squibb 58412.24 Cancer Advances 58712.25 Cancer Research Technology 59012.26 Celldex Therapeutics 59712.27 Center of Molecular Immunology 60312.28 CG Therapeutics 60612.29 Cosmo Pharmaceuticals 61112.30 CreaGene 61612.31 CSL 61912.32 CureVac 62312.33 Dainippon Sumitomo Pharma 62712.34 Dendreon 63212.35 DeveloGen 64112.36 Eisai 64412.37 Eli Lilly 64712.38 EntreMed 65012.39 Epeius Biotechnologies 65312.40 Etubics 65612.41 Galena Biopharma 66412.42 Generex 67112.43 GenOdyssee Pharmaceuticals 67712.44 Genticel 68012.45 Geron 68412.46 GlaxoSmithKline 69112.47 Gliknik 70012.48 GlobeImmune 70312.49 Gradalis 70912.50 Heat Biologics 71212.51 Hemispherx Biopharma 71512.52 Hoffmann-La Roche 71812.53 Ichor Medical Systems 72112.54 Idera Pharmaceuticals 72612.55 immatics biotechnologies 73112.56 ImmunoCellular Therapeutics 73412.57 ImmunoFrontier 73712.58 Immunotope 74312.59 Immunovaccine 74612.60 Inovio 75012.61 Intracel 75712.62 Introgen Therapeutics 76012.63 ISA Pharmaceuticals 76312.64 Jennerex Biotherapeutics 76712.65 Johnson & Johnson 77212.66 KAEL-GemVax 77612.67 Lipotek 78112.68 Mannkind 78412.69 MediGene 78912.70 Menarini 79412.71 Merck KGaA 79912.72 Micromet 80212.73 MolMed 80512.74 Mologen 80812.75 Momotaro-Gene 81212.76 Nemod Biotherapeutics 81512.77 Neovacs 82012.78 NIH – The US National Institute of Health 82312.79 Non-industrial Sources 82812.80 Northwest Biotherapeutics 83712.81 NovaRx 84112.82 OncoMune 84412.83 OncoTherapy Science 84712.84 Oncothyreon 85012.85 Oncovir 85812.86 Onyvax 86112.87 Orchestra Therapeutics 86412.88 Oxford BioMedica 86712.89 Pepscan Therapeutics 87212.90 Peptagen 87712.91 Pfizer 88012.92 PharmaForm 88412.93 Pharmexa 88912.94 Progenics Pharmaceuticals 89712.95 Protherics 90312.96 Radient Pharmaceuticals 90612.97 Receptor BioLogix 90912.98 responsif 91312.99 Sanofi 91712.100 Sarepta Therapeutics 92012.101 Scancell 92512.102 Shionogi 92812.103 TapImmune 93112.104 Therion Biologics 93412.105 Transgene 94112.106 United Biomedical 94612.107 Vaccinex 94912.108 Vaxil BioTherapeutics 95312.109 Vaximm 95812.110 Vaxon Biotech 96112.111 Vectura 96612.112 Vical 96912.113 Viragen 97612.114 Virionics 97912.115 ViroMed 98212.116 Zensun 98712.117 Zydus Cadila 99013 Disclaimer 99414 Drug Index 99515 Company Index 1002

1.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Cancer Vaccine Drugs 207Figure 2: The Drug-Target Competitive Landscape of Cancer Vaccine Drugs - Large Cluster 211Figure 3: The Drug-Target Competitive Landscape Cancer Vaccine Drugs - Smaller Clusters 212Figure 4: Head-to-Head Targeting Competitive Landscape of Cancer Vaccine Drugs 213Figure 5: Number of Companies per Ranking Level 500

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs